胸腺肽联合依替米星治疗肺结核的有效性分析

打开文本图片集

[关键词] 胸腺肽;依替米星;肺结核;不良反应

[中图分类号] R521          [文献标识码] B          [文章编号] 1673-9701（2021）15-0077-04

Effectiveness analysis of thymosin combined with etimicin in the treatment of tuberculosis

ZHANG Xue

Tuberculosis Ward Ⅲ， Shenyang Tenth People′s Hospital， Shenyang   110000， China

[Abstract] Objective To observe the effectiveness of thymosin combined with etimicin in the treatment of tuberculosis. Methods A total of 104 tuberculosis patients diagnosed and treated from May 2018 to May 2019 were selected and they were divided into the control group and the study group using a random number table method， with 52 cases in each group. The control group was treated with conventional treatment， and the study group was treated with thymosin and etimicin. The therapeutic efficacy and the rate of adverse reactions of two groups were compared. Changes and differences of related inflammatory factor indexes， such as interleukin-2 （IL-2）， interleukin-10 （IL-10）， tumor necrosis factor-α （TNF-α） and interferon-γ （IFN-γ） between the two groups were compared before and after treatment. Results The negative conversion ratio of sputum bacteria in the study group at different time points after treatment was higher than that in the control group， and the difference was statistically significant（P

[Key words] Thymosin; Etimicin; Tuberculosis;Adverse reaction

臨床中常见的一种传染病类型就是肺结核，研究指出，在每年临床中有大约800万的新增结核病病例;而因为肺结核而发生死亡的病例数则约300万左右[1]。（剩余6113字）

网站仅支持在线阅读（不支持PDF下载），如需保存文章，可以选择【打印】保存。